NanoViricides (NYSE:NNVC) Trading Down 4.9%

Posted by Latisha Jones on Aug 9th, 2024

NanoViricides, Inc. (NYSE:NNVC – Get Free Report)’s stock price traded down 4.9% on Wednesday . The stock traded as low as $1.95 and last traded at $1.96. 77,035 shares were traded during mid-day trading, a decline of 55% from the average session volume of 169,471 shares. The stock had previously closed at $2.06.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered NanoViricides from a “hold” rating to a “sell” rating in a research report on Wednesday, July 17th.

View Our Latest Analysis on NanoViricides

NanoViricides Price Performance

The company’s 50 day simple moving average is $2.08 and its 200 day simple moving average is $1.61. The stock has a market cap of $22.33 million, a P/E ratio of -2.30 and a beta of 0.97.

NanoViricides (NYSE:NNVC – Get Free Report) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.16) EPS for the quarter.

Institutional Trading of NanoViricides

An institutional investor recently raised its position in NanoViricides stock. Renaissance Technologies LLC lifted its stake in shares of NanoViricides, Inc. (NYSE:NNVC – Free Report) by 20.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 102,100 shares of the company’s stock after acquiring an additional 17,600 shares during the period. Renaissance Technologies LLC owned approximately 0.86% of NanoViricides worth $176,000 at the end of the most recent quarter. Institutional investors and hedge funds own 10.30% of the company’s stock.

NanoViricides Company Profile

(Get Free Report)

NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.